Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial

BACKGROUND: COVID-19 vaccine rollout is lagging in Africa, where there has been a high rate of SARS-CoV-2 infection. We aimed to evaluate the effect of SARS-CoV-2 infection before vaccination with the ChAdOx-nCoV19 (AZD1222) vaccine on antibody responses through to 180 days. METHODS: We did an unmas...

Descripción completa

Detalles Bibliográficos
Autores principales: Madhi, Shabir A, Kwatra, Gaurav, Richardson, Simone I, Koen, Anthonet L, Baillie, Vicky, Cutland, Clare L, Fairlie, Lee, Padayachee, Sherman D, Dheda, Keertan, Barnabas, Shaun L, Bhorat, Qasim Ebrahim, Briner, Carmen, Ahmed, Khatija, Aley, Parvinder K, Bhikha, Sutika, Bhorat, A E, Esmail, Aliasgar, Horne, Elizea, Kaldine, Haajira, Mukendi, Christian K, Madzorera, Vimbai Sharon, Manamela, Nelia P, Masilela, Mduduzi, Hermanus, S Tandile, Motlou, Thopisang, Mzindle, Nonkululeko, Oelofse, Suzette, Patel, Faeezah, Rhead, Sarah, Rossouw, Lindie, Taoushanis, Carol, van Eck, Samuel, Lambe, Teresa, Gilbert, Sarah C, Pollard, Andrew J, Moore, Penny L, Izu, Alane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584570/
https://www.ncbi.nlm.nih.gov/pubmed/36273491
http://dx.doi.org/10.1016/S1473-3099(22)00596-5

Ejemplares similares

Ejemplares similares